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Background: Drug use evaluation is a performance improvement method that focuses on evaluating and
improving drug use process to achieve optimal patient outcomes. Drug use evaluation helps in identifying,
preventing or resolving actual and potential drug related problems. The objective of the study was to evaluate the
use of cotrimoxazole as preventive therapy in people living with HIV/AIDS in Boru Meda Hospital, Northeast
Ethiopia.
Methods: A retrospective drug use evaluation was conducted on patients’ medical history records based on a
validated drug use evaluation criteria according to the national guideline. Medical history records of 248 patients
were selected using systematic sampling method.
Results: The result showed that 49.6% of the patients were at WHO clinical stage III at the start of cotrimoxazole
preventive therapy. In this study, the use of cotrimoxazole preventive therapy was consistent with the guideline in
the rationale for indication (97.98%), dose (96.77%), and its use despite the presence of contraindications (91.93%).
Problems regarding drug-drug interaction were identified in 49.59% of cases, and 20.97% of patients discontinued
cotrimoxazole preventive therapy due to different reasons.
Conclusions: In most patients cotrimoxazole preventive therapy was consistent with the national guideline
regarding the rationale for indication, dose, discontinuation and its use in the presence of contraindications.
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Rational drug use is concerned with promoting quality of
care and cost- effective therapy, preventing unnecessary
exposure to side effects, maximizing therapeutic benefits,
and improving patient compliance [1]. Drug use evalu-
ation (DUE) is one of the methods used in combating the
development of bacterial resistant to anti-microbial agents
and improving therapy [2].
Cotrimoxazole (CTX), a fixed dose combination of
sulfamethoxazole and trimethoprim, is a broad spectrum
antimicrobial agent that targets a range of aerobic gram
positive and gram negative organisms, fungi and proto-
zoa [3,4]. CTX is preferable for both primary and* Correspondence: berhanu.grs@gmail.com
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reproduction in any medium, provided the orsecondary prophylaxis of pneumocystis jirvoeic pneumo-
nia (PCP) in adults and adolescents [5,6]. The World
Health Organization (WHO) and the Joint United Nations
Programme on HIV/AIDS (UNAIDS) have recently rec-
ommended the use of co-trimoxazole prophylaxis for
HIV-infected adults in Africa with symptomatic HIV dis-
ease (stage II, III or IV of the WHO classification of HIV
infection and disease) and for asymptomatic individuals
who have a CD4 T-lymphocyte count of ≤500×106/l or
total lymphocyte count (TLC) equivalent [7].
The recommended dose for adult and Adolescents is
two single strength tablets of CTX (tablets of 80 mg
Trimethoprim and 400 mg Sulphamethoxazole) or one
double strength tablet (1 tablet of 160 mg Trimetho-
prim and 800 mg sulfamethoxazole) daily or three
times per week. In addition, children in the age rangeLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Baseline characteristics of PLWHA at the start of
CPT on BMH before February 2012







Co morbid illness TB 29 (11.69)
Fungal infection 31 (12.75)
PCP 2 (0.8)
Others 18 (7.26)
Laboratory results CD4 count <350 cell/mm3 221 (89.11)
Hemoglobin <7 g/dl 4 (1.61)
Platelet count < 50,000 cells/dl 4 (1.61)
Neutrophil count < 750 cells/dl 3 (1.2)
ALT > 115 IU/L (for males) >90 IU/L
(for females)
3 (1.2)
ALT- alanine transaminase, IU- international unit.
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6 years-14 years or (15-30 kg) take (400 mg/80 mg) CTX
and >14 years or >30 kg take (800/60 mg) CTX. Adverse
conditions that lead to discontinuation of CTX are itching
(with mucocutaneous lesion and or fever), significant rash,
fever, Steven Johnson syndrome and sever anemia [4].
CTX preventive therapy (CPT) is a simple well toler-
ated and cost effective intervention which can extend
and improve the quality of life for people living with
HIV/AIDS (PLWHA) including those on antiretroviral
therapy (ART). CPT is associated with a 25-46% reduc-
tion in mortality among individuals infected with HIV in
sub-Saharan Africa even in areas of high bacterial resist-
ance to the antibiotic [7,8].
Despite the proven clinical benefits of CTX and rec-
ommendation by WHO, its routine use in developing
countries particularly in sub-Saharan Africa has remain
limited [8]. CPT is effective at preventing a number of
opportunistic infections (OIs) among HIV positive indi-
viduals initiating ART. Although the drug is cheap and
widely available, many countries failed to implement pol-
icies to provide nation wide coverage of the drug [9].
Use of judiciously selected drugs with a valid set of
guidelines will bring success not only to health care sys-
tem of the country but also to the whole socio-economic
development [6].
Antibiotics represent approximately 30% of the acute
hospital care expenditure and they are prescribed for 20-
50% of patients. The development of drug resistant organ-
isms may emerge as a result of many factors including ir-
rational use of drugs [2]. The inevitable consequences of
the emergence of antimicrobial resistant pathogens fuels
an ever increasing need for new drugs and contribute to
the rising cost of medical care [10].
Retrospective DUE addresses issues of indications, con-
tra indications, drug interactions, dosage, therapeutic du-
plications and patient monitoring patterns. In addition it
provides information that opens ways to provide feedback
for prescribers on their performance in implementing
treatment protocols and their compliance with preset ap-
proved guidelines for the use of each medication. In deal-
ing with the fight against health problems like HIV/AIDS,
that have deep rooted socio-economic impact, it is quite
useful to evaluate the effectiveness of programs for better
outcomes. Thus DUE should be incorporated as one of
such monitoring systems in the health care system of the
country in response to the issue of AIDS epidemic and
OPIs [11]. Therefore, the aim of this study was to evaluate
the use of cotrimoxazole as preventive therapy in PLWHA
Boru Meda Hospital.
Methods
A retrospective drug use evaluation was conducted on
patients’ medical history records in Boru Meda Hospital(BMH), Northeast Ethiopia from May 22-30/2012. The
hospital is a rural hospital located 4 kilo meters away
from Dessie town and comprised of 6 general practi-
tioners, 40 nurses, 16 pharmacy technicians and 4 X-ray
technicians with a total beds of 80. A total of 701 pa-
tients were receiving CPT before February 2012. Medical
history records of 248 patients out 701 were selected
using systematic sampling method from sequentially ar-
ranged medical records.
The independent variables were age, sex, patients’ clinical
condition and laboratory results. Whereas the dependent
variables include indication, contraindication, drug-drug
interaction, dosage and discontinuation of CPT.
Data collection format containing the variables to be
measured was developed and used to collect data. The
collected data were filtered, categorized and the results
were analyzed using SPSS version 15, interpreted and
presented using tables and charts.
Ethical clearance was obtained from College of Medicine
and Health Sciences, Wollo University Institutional Review
Committee (IRC), and permission was sought from BMH.
Results
Out of 248, 123 (49.60%) patients were at WHO clinical
stage III HIV infection at the start of CPT. Even though
co morbid illnesses were not documented for most
(67%) of the patients, the prevalence of tuberculosis
(TB) and fungal infections were 11.69% and 12.50%, re-
spectively. Majority of the patients 221 (89.11%) were
found to have CD4 count of less than 350cell/mm3
(Table 1).
The result also showed that 243 (97.98%) patients were
in line with the national CPT guideline regarding to
Table 3 Cotrimoxazole use despite the presence of
contraindications among PLWHA in BMH before
February 2012
Condition evidence for contra use of CPT Number (%)
Severe anemia (Hg < 7 g/dl of blood) 5 (25)
Elevated liver enzymes (SGPT > 115 IU/L for males and
90 IU/L for female)
3 (15)
Severe neutrophil (<750 cell/dl) 3 (15)
Severe thrombocytopenia (<50,000 cells/dl) 4 (20)
1st trimester of pregnancy 5 (25)
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correct dose of CTX (Table 2). The medical history
cards showed that 20 (8.06%) patients were using CTX
against contraindications out of which 5 (25%) devel-
oped sever anemia (Table 3).
In 123 (49.6%) cases CTX interaction with zidovudine
(AZT) was documented and there were no other drug-
drug interactions involving CTX. Among 52 patients
who discontinued CPT, 10 (19.25%) and 14 (26.92%)
were due to improvement of CD4 (>350 cells/mm3) and
peptic ulcer disease, respectively (Table 4).Sulfa allergy _
Total 20 (8.06)Discussion
One of the most pressing problems facing health pro-
viders and administers in many countries is insuring ra-
tional drug use, which implies an individual approach to
patient treatment. The presence of standard treatment
guidelines and drug formularies for selected drugs in a
health facility does not ensure that drugs are prescribed
and used correctly. One mechanism to ensure correct
use of drug is DUE [2].
In this study the use of CTX among PLWHA was con-
sistent with the national guideline in the rationale for indi-
cation in most (97.98%) patients. In 2% of the patients (who
were WHO clinical stage I and CD4 level >350 cells/ml)
CPT was started without any symptomatic disease. The
CTX dosage prescribed for most patients were appro-
priate except in 1.6% of patients in the age range
6 months to 14 years. This might leads to insufficient
and inappropriate treatment.
The finding on the rationale for indication and appro-
priate dose were in line with the study conducted in
Jimma University Specialized Hospital in which all cases
of the indication to start and dose were according to the
national guideline [12]. On the contrary, the result for
CTX dose was slightly different from the study done in
Hawasa referral hospital in which 87% of the cases on
usage of CTX dose were according to the national
guideline [10].Table 2 Cotrimoxazole dosage prescribed for PLWHA in
BMH before February 2012
Age
distribution






<6 month 3 (1.2) _ 3 (1.2)
6 month-5 yr 4 (1.61) 4 (1.61) 8 (3.23)
6-14 yr 14 (5.64) 4 (1.61) 18 (7.25)
15-49 yr 202 (81.45) _ 202 (81.45)
>50 yr 17 (6.85) _ 17 (6.85)
Total 240 (96.77) 8 (3.23) 248 (100)CTX was used despite contra indications in cases of
8.06% and in 91.93% of cases the drug was used without
any contraindications. This is in agreement with a re-
search done in Jimma [12], which showed 98.3% of the
cases were in accordance with the guideline. The na-
tional guideline suggests the importance of monitoring
drug usage for patients with severe anemia taking CTX
and AZT [1]. In 49.59% of cases CPT had interactions
with AZT, which is far from 98.3% of patients in Jimma
[12]. The interaction of these drugs causes bone marrow
suppression and thereby hematological abnormalities
[13]. This in turn results in lack of adherence and poor
patient outcomes.
WHO and the Federal Ministry of Health of Ethiopia
recommended the reasons for discontinuation of CPT in
PLWHA for better treatment outcome and for preventing
potential drug related problems [6,8]. Among 52 patients
who discounted CPT, 25% of them were without any doc-
umented data for their discontinuation and 23% of them
discontinued due to both skin rash and pregnancy. Most
patients discontinued CPT due to peptic ulcer (19.25%)
and CD4 improvement (26.92%). The result for discon-
tinuation of CPT (75%) which was in agreement with the
national guideline and with the study done in Jimma Uni-
versity Specialized Hospital [12].Table 4 Common reasons for discontinuation of CPT
among PLWHA in BMH before February 2012
Reason for discontinuation Number (%)
Peptic ulcer 10 (19.21)
Skin rash 6 (11.53)
Sever anemia 3 (5.77)
Pregnancy 6 (11.53)
CD4 > 350 cells/mm3 14 (26.92)
Others (not recorded) 13 (25.00)
Total 52 (20.97)
Geresu et al. BMC Pharmacology and Toxicology 2014, 15:4 Page 4 of 4
http://www.biomedcentral.com/2050-6511/15/4Patients discontinue CPT when their CD4 count was
restored to the recommended level and this in turn de-
creases pill burden in patients taking ART and thereby
increases treatment adherence. If discontinuation is not
according to the guideline, it may lead to antimicrobial
resistance, fuelling an ever increasing need for new
drugs and contributing the rising cost of medical care.
To date, there are no published studies conducted on
evaluation of cotrimoxazole use for prophylaxis in
PLWHA outside Ethiopia and hence it was not possible
to compare the practice of this hospital with practices of
other clinical settings. The findings were discussed in re-
lation to the 2005 CPT guideline of Ethiopia and few
studies done in Ethiopia.
Conclusions
In summary the use of CPT among PLWHA was con-
sistent with the national guideline regarding to rationale
for indication, dose, discontinuation and its use despite
the presence of contraindications in most patients, how-
ever, problems regarding drug- drug interaction were
identified in more than half of the patients.
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